WHAT IS CLAIMED IS:

1. Use of benralizumab in the manufacture of a medicament for treating chronic obstructive pulmonary disease (COPD) in a human COPD patient, wherein a dose of the medicament comprising 100 mg of benralizumab is to be administered to the patient once every four weeks for twelve weeks, and then once every eight weeks.

2. The use of claim 1, wherein the patient has a blood eosinophil count of at least 200 eosinophils/μL prior to the administration.

3. The use of claim 2, wherein the patient has a blood eosinophil count of at least 300 eosinophils/μL prior to the administration.

4. The use of claim 3, wherein the patient has a blood eosinophil count of at least 400 eosinophils/μL prior to the administration.

5. The use of any one of claims 1-4, wherein the patient has severe or very severe COPD as defined by Global Initiative for Chronic Obstructive Lung Disease (GOLD).

6. The use of any one of claims 1-5, wherein the administration reduces the exacerbation rate of COPD in the patient.

7. The use of any one of claims 1-6, wherein the administration increases the patient's forced expiratory volume in one second (FEV_1).

8. The use of any one of claims 1-7, wherein the administration increases the patient's forced vital capacity (FVC).

9. The use of any one of claims 1-8, wherein the administration improves a COPD questionnaire score assessing COPD symptoms in the patient.

10. The use of any one of claims 1-9, wherein the patient uses corticosteroids, long-acting β2 agonists, and tiotropium.

11. The use of any one of claims 1-10, wherein the administration is subcutaneous.